Plain-English translation of NCT07680556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a pilot study testing whether supervised high-intensity interval training (exercise) can help patients with advanced kidney cancer respond better to dual immunotherapy (a combination of two medications called nivolumab and ipilimumab). Early research in mice suggests that exercise may improve how the body's immune system works against tumors, but doctors haven't yet tested this in kidney cancer patients receiving this specific treatment.
Many patients with advanced kidney cancer don't respond well to immunotherapy, and some experience serious side effects. Animal studies show that exercise might improve the tumor environment and boost immune cell activity, but no one has studied whether this approach actually works in people receiving this medication.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to either do supervised high-intensity interval training (short bursts of intense exercise followed by recovery periods) during your immunotherapy treatment, or receive usual care with written information about physical activity. The exercise group will work with trainers who monitor your fitness and safety throughout your treatment. The study will track how well you tolerate the exercise, how you feel, and how your body responds to the medication.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Netherlands